Antibody–Drug Conjugate to Treat Meningiomas

Kai Chen; Yingnan Si; Jianfa Ou; Jia-Shiung Guan; Seulhee Kim; Patrick Ernst; Ya Zhang; Lufang Zhou; Xiaosi Han; Xiaoguang (Margaret) Liu

doi:10.3390/ph14050427

Pharmaceuticals (May 2021)

Antibody–Drug Conjugate to Treat Meningiomas

Kai Chen,
Yingnan Si,
Jianfa Ou,
Jia-Shiung Guan,
Seulhee Kim,
Patrick Ernst,
Ya Zhang,
Lufang Zhou,
Xiaosi Han,
Xiaoguang (Margaret) Liu

Affiliations

Kai Chen: Department of Biomedical Engineering, University of Alabama at Birmingham (UAB), 1825 University Blvd, Birmingham, AL 35294, USA
Yingnan Si: Department of Biomedical Engineering, University of Alabama at Birmingham (UAB), 1825 University Blvd, Birmingham, AL 35294, USA
Jianfa Ou: Department of Biomedical Engineering, University of Alabama at Birmingham (UAB), 1825 University Blvd, Birmingham, AL 35294, USA
Jia-Shiung Guan: Department of Medicine, University of Alabama at Birmingham, 703 19th Street South, Birmingham, AL 35294, USA
Seulhee Kim: Department of Biomedical Engineering, University of Alabama at Birmingham (UAB), 1825 University Blvd, Birmingham, AL 35294, USA
Patrick Ernst: Department of Medicine, University of Alabama at Birmingham, 703 19th Street South, Birmingham, AL 35294, USA
Ya Zhang: Department of Biomedical Engineering, University of Alabama at Birmingham (UAB), 1825 University Blvd, Birmingham, AL 35294, USA
Lufang Zhou: Department of Biomedical Engineering, University of Alabama at Birmingham (UAB), 1825 University Blvd, Birmingham, AL 35294, USA
Xiaosi Han: Department of Neurology, University of Alabama at Birmingham, 1824 6th Avenue South, Birmingham, AL 35294, USA
Xiaoguang (Margaret) Liu: Department of Biomedical Engineering, University of Alabama at Birmingham (UAB), 1825 University Blvd, Birmingham, AL 35294, USA

DOI: https://doi.org/10.3390/ph14050427
Journal volume & issue: Vol. 14, no. 5
p. 427

Abstract

Read online

Meningiomas are primary tumors of the central nervous system with high recurrence. It has been reported that somatostatin receptor 2 (SSTR2) is highly expressed in most meningiomas, but there is no effective targeted therapy approved to control meningiomas. This study aimed to develop and evaluate an anti-SSTR2 antibody–drug conjugate (ADC) to target and treat meningiomas. The meningioma targeting, circulation stability, toxicity, and anti-tumor efficacy of SSTR2 ADC were evaluated using cell lines and/or an intracranial xenograft mouse model. The flow cytometry analysis showed that the anti-SSTR2 mAb had a high binding rate of >98% to meningioma CH157-MN cells but a low binding rate of 50 value of <10 nM. In vivo anti-tumor efficacy showed that the anti-SSTR2 ADC with doses of 8 and 16 mg/kg body weight effectively inhibited tumor growth. This study demonstrated that the anti-SSTR2 ADC can target meningioma and reduce the tumor growth.

Published in Pharmaceuticals

ISSN: 1424-8247 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Pharmacy and materia medica
Website: http://www.mdpi.com/journal/pharmaceuticals/

About the journal

Abstract

Keywords